ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2675

RANTES and CXCL10 as Potential Tear-Based Biomarkers Associated with Ocular Damage in Pediatric Chronic Anterior Uveitis

Ilaria Maccora1, Mariia Pavlenko2, Mekibib Altaye3, Hermine Brunner4, Alexandra Duell4, Megan Quinlan-Waters5, Alyssa Sproles6, Sherry Thornton4, Grant Schulert4, Virginia Miraldi Utz4 and Sheila Angeles-Han6, 1Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, 2Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, 3Cincinnati Children's Hospital, Cincinnati, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, CCHMC, 6Cincinnati Children's Hospital, Cincinnati, OH

Meeting: ACR Convergence 2025

Keywords: Biomarkers, cytokines, Eye Disorders, Juvenile idiopathic arthritis, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 29, 2025

Title: Abstracts: Pediatric Rheumatology – Clinical III (2675–2680)

Session Type: Abstract Session

Session Time: 11:30AM-11:45AM

Background/Purpose: Pediatric chronic anterior uveitis (CAU) leads to sight-threatening complications in approximately 50% of affected children. Among complications, cataract and glaucoma are among the most common ocular complications of CAU. We aim to identify tear-based biomarkers associated with ocular damage in pediatric CAU.

Methods: This cross-sectional study included children ≥5 years old diagnosed with CAU (juvenile idiopathic arthritis-associated (JIA-U) or idiopathic (iCAU)) from our registry at CCHMC. Tear samples were collected from both eyes by Schirmer strips. Ocular complications included cataract, glaucoma, synechiae, band keratopathy, macular edema, epiretinal membrane, and optic disc oedema. Levels of S100A8, A9, and A12 were measured by ELISA, and IL-18, IL-8, CXCL10 (IP-10), MCP-1, RANTES, and sICAM-1 by Luminex assays. Biomarker levels were compared by the number of ocular complications (0, 1, >1). An exploratory Spearman correlation (ρ) analysis was performed and a Heatmap was developed to identify potential significant associations. A p-value < 0.05 was considered significant.

Results: Forty-one children (29 JIA-U; 12 iCAU) with CAU contributed 121 tear samples (86 JIA-U; 35 iCAU) (Table 1), of whom 77 samples are from eyes with complications (51 by JIA-U and 26 by iCAU, χ²2.41, p=0.088). We observed significant differences regarding the number of complications between JIA-U vs iCAU (mean 1.88 vs 2.15, p< 0.001). We observed an increased level of RANTES in children with complications compared to those without complications (0.752 vs 0.389, p=0.028), and when considering the number of complications [0, 1, or >1] (0.389 vs 0.675 vs 0.824 respectively, p=0.022) (Figure 1A). Conversely, CXCL10 was decreased in children with complications (2.82 vs 2.99, p=0.010), and when stratified by the number of complications (2.991 vs 2.881 vs 2.785 respectively, p=0.004, Figure 1B). As shown in Figure 2, there were several significant correlations between the level of candidate biomarkers and ocular parameters: RANTES was positively correlated with the presence of complications (ρ=271, p=0.005) and glaucoma (ρ=306,p=0.015), while CXCL10 was negatively correlated with the presence of complications(ρ=0.27, p=0.005, the number of complications (ρ=0.31,p=0.006), and the presence of macular oedema/and papillitis (ρ=245,p=0.031). Moreover we found a positive correlation between S100A9 and the presence of cataract (ρ=384,p=0.003) and a negative correlation with uveitis activity (ρ=292,p=0.007).

Conclusion: We identified RANTES, CXCL10 and S100A9 as potential tear-based biomarkers associated with ocular damage in pediatric patients with CAU. RANTES appears to be elevated with ocular complications, whereas CXCL10 is decreased. The role of RANTES has been demonstrated in experimental autoimmune uveitis models and patients with uveitis. It has also been shown to differentiate patients with glaucoma. Further, we identified CXCL10 and S100A9 correlations with specific complications. Next steps are to determine biomarkers that are associated with specific ocular complications and differentiate activity from damage (chronicity).

Supporting image 1Table 1. Clinical Characteristics of Children with Chronic Anterior Uveitis

Supporting image 2Figure 1: Significant differences in complications and A) CXCL10 and B) RANTES with pairwise comparison that indicate differences.

Supporting image 3Figure 2: Heatmap representing the correlations among the logarithmic value of cytokines and chemokines and the different variables considered. The significant correlations are identified with one or two stars (0.05 >p>0.009 and p < 0.009 respectively). The blue color represents negative correlations, while red color positive correlations


Disclosures: I. Maccora: None; M. Pavlenko: None; M. Altaye: None; H. Brunner: AbbVie, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, EMD Serono, 2, F. Hoffmann-La Roche, 2, Genentech, 5, GlaxoSmithKline, 2, Merck, 2, Novartis, 2, Pfizer, 2, 5, Sanofi, 2, UCB, 2; A. Duell: None; M. Quinlan-Waters: None; A. Sproles: None; S. Thornton: None; G. Schulert: IpiNovoyx, 5, Novartis, 2, SOBI, 2; V. Miraldi Utz: None; S. Angeles-Han: None.

To cite this abstract in AMA style:

Maccora I, Pavlenko M, Altaye M, Brunner H, Duell A, Quinlan-Waters M, Sproles A, Thornton S, Schulert G, Miraldi Utz V, Angeles-Han S. RANTES and CXCL10 as Potential Tear-Based Biomarkers Associated with Ocular Damage in Pediatric Chronic Anterior Uveitis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/rantes-and-cxcl10-as-potential-tear-based-biomarkers-associated-with-ocular-damage-in-pediatric-chronic-anterior-uveitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rantes-and-cxcl10-as-potential-tear-based-biomarkers-associated-with-ocular-damage-in-pediatric-chronic-anterior-uveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology